DPT Scientist to be Featured in Webcast on Topical Drug Sector
R&D manager of formulation and process development at DPT Laboratories, Michael Lowenborg, will be featured in a webcast on 7 December, offering insights from leading pharmaceutical industry experts on ‘Optimizing Topical Drug Formulations and Manufacturing’.
The 60-minute webcast, at 2pm EST, is presented by PharmaceuticalTechnology magazine, which notes that the topic is increasingly important to pharmaceutical companies seeking innovative ways to improve drug delivery and patient compliance.
Lowenborg has 15 years experience in the industry working on semi-solid and liquid formulations, primarily topical skin treatment products. He worked for several large companies before joining DPT almost eight years ago.
DPT offers sterile and non-sterile pharmaceutical development and manufacturing expertise in a variety of topical formulations, including creams, foams, gels, lotions and ointments. The company has established Centers of Excellence for Research & Development and for Semi-solids & Liquids in San Antonio, TX, and a Center for Sterile & Specialty Products in Lakewood, NJ.
"The semi-solids market, including topical drug formulations, plays an important role for the pharmaceutical industry and DPT is a leader in the sector," said Tom Mitchell, director of marketing at DPT. "We have made a significant commitment to the semi-solids market, with continued investments in our operations including upgrades at our facilities in 2010 and again in 2011."
According to Patricia Van Arnum, senior editor of Pharmaceutical Technology, the webcast ‘provides insight on recent advances in topical drug formulations, the latest regulatory/pharmacopoeial requirements in product quality and product performance, and strategies to optimize manufacturing for topical drug products’.
In addition to Lowenborg, speakers include: Vinod Shah, PhD, chair of the special interest group, Regulatory Science of the International Pharmaceutical Federation and distinguished pharmaceutical scientist and consultant to the US Pharmacopeia and Majella Lane, PhD, senior lecturer in pharmaceutics at the School of Pharmacy at the University of London.